vs
亚玛芬体育（AS）与HAEMONETICS CORP（HAE）财务数据对比。点击上方公司名可切换其他公司
亚玛芬体育的季度营收约是HAEMONETICS CORP的3.0倍（$1.1B vs $346.4M），HAEMONETICS CORP净利率更高（28.1% vs 1.8%，领先26.3%），HAEMONETICS CORP自由现金流更多（$209.9M vs $92.2M）
亚玛芬体育是芬兰跨国运动装备企业，总部位于赫尔辛基，成立于1950年。早年为涉足烟草贸易、航运、出版等领域的多元化工业集团，后逐步转型专注于体育用品的生产与营销，现有员工超9700人，2018年起成为中国安踏体育旗下子公司。
豪洛捷（Haemonetics）是全球血液与血浆供应及服务提供商，于20世纪70年代由艾伦·（杰克）·莱瑟姆博士在马萨诸塞州内蒂克创立，业务围绕血液相关产品及配套服务展开，为全球医疗领域提供血液管理相关的专业解决方案。
AS vs HAE — 直观对比
营收规模更大
AS
是对方的3.0倍
$346.4M
净利率更高
HAE
高出26.3%
1.8%
自由现金流更多
HAE
多$117.7M
$92.2M
损益表 — Q1 FY2024 vs Q4 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $346.4M |
| 净利润 | $19.0M | $97.3M |
| 毛利率 | 52.8% | 57.2% |
| 营业利润率 | 12.4% | 36.1% |
| 净利率 | 1.8% | 28.1% |
| 营收同比 | — | 4.8% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $0.05 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASHAE
| Q1 26 | — | $346.4M | ||
| Q4 25 | — | $339.0M | ||
| Q3 25 | — | $327.3M | ||
| Q2 25 | — | $321.4M | ||
| Q1 25 | — | $330.6M | ||
| Q4 24 | — | $348.5M | ||
| Q3 24 | — | $345.5M | ||
| Q2 24 | — | $336.2M |
净利润ASHAE
| Q1 26 | — | $97.3M | ||
| Q4 25 | — | $44.7M | ||
| Q3 25 | — | $38.7M | ||
| Q2 25 | — | $34.0M | ||
| Q1 25 | — | $58.0M | ||
| Q4 24 | — | $37.5M | ||
| Q3 24 | — | $33.8M | ||
| Q2 24 | — | $38.4M |
毛利率ASHAE
| Q1 26 | — | 57.2% | ||
| Q4 25 | — | 59.7% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 59.8% | ||
| Q1 25 | — | 58.4% | ||
| Q4 24 | — | 55.5% | ||
| Q3 24 | — | 54.2% | ||
| Q2 24 | — | 52.0% |
营业利润率ASHAE
| Q1 26 | — | 36.1% | ||
| Q4 25 | — | 19.9% | ||
| Q3 25 | — | 17.9% | ||
| Q2 25 | — | 16.8% | ||
| Q1 25 | — | 21.6% | ||
| Q4 24 | — | 16.9% | ||
| Q3 24 | — | 15.0% | ||
| Q2 24 | — | 11.8% |
净利率ASHAE
| Q1 26 | — | 28.1% | ||
| Q4 25 | — | 13.2% | ||
| Q3 25 | — | 11.8% | ||
| Q2 25 | — | 10.6% | ||
| Q1 25 | — | 17.5% | ||
| Q4 24 | — | 10.8% | ||
| Q3 24 | — | 9.8% | ||
| Q2 24 | — | 11.4% |
每股收益（稀释后）ASHAE
| Q1 26 | — | — | ||
| Q4 25 | — | $0.95 | ||
| Q3 25 | — | $0.81 | ||
| Q2 25 | — | $0.70 | ||
| Q1 25 | — | $1.17 | ||
| Q4 24 | — | $0.74 | ||
| Q3 24 | — | $0.66 | ||
| Q2 24 | — | $0.74 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $245.4M |
| 总债务越低越好 | — | $1.2B |
| 股东权益账面价值 | — | $796.3M |
| 总资产 | — | $2.4B |
| 负债/权益比越低杠杆越低 | — | 1.53× |
8季度趋势，按日历期对齐
现金及短期投资ASHAE
| Q1 26 | — | $245.4M | ||
| Q4 25 | — | $363.4M | ||
| Q3 25 | — | $296.4M | ||
| Q2 25 | — | $292.9M | ||
| Q1 25 | — | $306.8M | ||
| Q4 24 | — | $320.8M | ||
| Q3 24 | — | $299.3M | ||
| Q2 24 | — | $344.4M |
总债务ASHAE
| Q1 26 | — | $1.2B | ||
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益ASHAE
| Q1 26 | — | $796.3M | ||
| Q4 25 | — | $911.5M | ||
| Q3 25 | — | $849.2M | ||
| Q2 25 | — | $882.3M | ||
| Q1 25 | — | $820.8M | ||
| Q4 24 | — | $906.9M | ||
| Q3 24 | — | $878.9M | ||
| Q2 24 | — | $905.4M |
总资产ASHAE
| Q1 26 | — | $2.4B | ||
| Q4 25 | — | $2.5B | ||
| Q3 25 | — | $2.4B | ||
| Q2 25 | — | $2.5B | ||
| Q1 25 | — | $2.5B | ||
| Q4 24 | — | $2.5B | ||
| Q3 24 | — | $2.5B | ||
| Q2 24 | — | $2.5B |
负债/权益比ASHAE
| Q1 26 | — | 1.53× | ||
| Q4 25 | — | 1.34× | ||
| Q3 25 | — | 1.44× | ||
| Q2 25 | — | 1.39× | ||
| Q1 25 | — | 1.49× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $114.3M | $293.2M |
| 自由现金流经营现金流 - 资本支出 | $92.2M | $209.9M |
| 自由现金流率自由现金流/营收 | 8.8% | 60.6% |
| 资本支出强度资本支出/营收 | 2.1% | 9.5% |
| 现金转化率经营现金流/净利润 | 6.02× | 3.01× |
| 过去12个月自由现金流最近4个季度 | — | $417.1M |
8季度趋势，按日历期对齐
经营现金流ASHAE
| Q1 26 | — | $293.2M | ||
| Q4 25 | — | $93.6M | ||
| Q3 25 | — | $111.3M | ||
| Q2 25 | — | $17.4M | ||
| Q1 25 | — | $116.6M | ||
| Q4 24 | — | $43.8M | ||
| Q3 24 | — | $48.8M | ||
| Q2 24 | — | $-27.4M |
自由现金流ASHAE
| Q1 26 | — | $209.9M | ||
| Q4 25 | — | $87.2M | ||
| Q3 25 | — | $106.3M | ||
| Q2 25 | — | $13.6M | ||
| Q1 25 | — | $100.9M | ||
| Q4 24 | — | $35.2M | ||
| Q3 24 | — | $39.4M | ||
| Q2 24 | — | $-33.1M |
自由现金流率ASHAE
| Q1 26 | — | 60.6% | ||
| Q4 25 | — | 25.7% | ||
| Q3 25 | — | 32.5% | ||
| Q2 25 | — | 4.2% | ||
| Q1 25 | — | 30.5% | ||
| Q4 24 | — | 10.1% | ||
| Q3 24 | — | 11.4% | ||
| Q2 24 | — | -9.8% |
资本支出强度ASHAE
| Q1 26 | — | 9.5% | ||
| Q4 25 | — | 1.9% | ||
| Q3 25 | — | 1.5% | ||
| Q2 25 | — | 1.2% | ||
| Q1 25 | — | 4.7% | ||
| Q4 24 | — | 2.5% | ||
| Q3 24 | — | 2.7% | ||
| Q2 24 | — | 1.7% |
现金转化率ASHAE
| Q1 26 | — | 3.01× | ||
| Q4 25 | — | 2.09× | ||
| Q3 25 | — | 2.88× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | — | 2.01× | ||
| Q4 24 | — | 1.17× | ||
| Q3 24 | — | 1.44× | ||
| Q2 24 | — | -0.71× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AS
| Americas2 | $409.6M | 39% |
| EMEA1 | $356.9M | 34% |
| Greater China3 | $205.6M | 20% |
| Asia Pacific4 | $78.2M | 7% |
HAE
| Hospital | $159.6M | 46% |
| Plasma | $130.3M | 38% |
| Blood Center | $56.4M | 16% |
